Team Stéphane DALLE – Eric RENARD
Innovative therapeutics for diabetes
Stephane
Dalle
DR2, Inserm
Éric
Renard
PU-PH1, UM
The aim of the “Innovative therapeutics for diabetes” team is to develop fundamental, translational and clinical research to improve the treatment of diabetes in its various clinical and pathophysiological forms based on multidisciplinary expertise. The team composed of researchers, research professor, hospital practitioners and engineers, is working to develop new therapeutic strategies aimed at correcting, restoring or preserving the insulin secretory function of pancreatic beta cells in diabetes.
Pancreatic beta cells are the only cells capable of synthesizing and secreting insulin. While autoimmune mechanisms lead to the loss of beta cells in type 1 diabetes, the mechanisms involved in type 2 diabetes are multiple and complex, leading to a functional deficiency in insulin secretion and a reduction in beta cell mass. Our research projects aim to develop innovative automated insulin delivery systems to reduce insulin delivery close to the physiological level, improve pancreatic islet transplantation, and define new therapeutic targets and strategies to prevent beta cell dysfunction and death.
Human islet (insulin : green ; glucagon : red)
Histological section of mouse pancreas showing an inflammatory reaction
Team leader
Stephane
Dalle
IGF Sud 119
04 34 35 92 03Know more >
Stephane
Dalle
DR2, Inserm
Team: Stéphane Dalle - Éric Renard
EDUCATION
-
1998PhD, Sciences University, Montpellier, France
-
2005HDR diploma, Medicine University, Montpellier, France
POSITIONS HELD
-
2011-Research Director, Team leader Innovative Therapeutics for Diabetes, IGF
-
2005-2010Researcher, Team leader AVENIR program Inserm, IGF, Montpellier
-
2001-2004Postdoctoral fellowship, Research group leader, Inserm U376, Montpellier
-
1999-2001Postdoctoral fellowship, University of California San Diego-La Jolla, USA
HONORS / RESPONSABILITIES
-
2018-Member scientific advisory board CEED Diabetes (Strasbourg)
-
2017-2020Member scientific advisory board French Biology Society
-
2017-2019Member HCERES evaluation committee
-
2017-2019Member scientific advisory board Société Francophone du Diabète
-
2016-2021Member Inserm committee Commission Scientifique Spécialisée 3 (CSS3)
-
2013-2020Member scientific advisory board IGF
-
2010-2012Member scientific advisory board French Société Francophone du Diabète
-
2008-2013Leader clinical platform for human pancreatic islet isolation, IRMB, Montpellier
-
2010Award chercheur d’avenir, Région Languedoc-Roussillon/Occitanie, France
-
2004Award Avenir program, Inserm, France
-
2003Award jeune chercheur, Association pour la Recherche sur le Diabète et le Cancer, France
SKILLS / EXPERTISE
- Cellular biologist/biochemist specialized in the physiology and pathophysiology of pancreatic beta cells, islets of Langerhans, and research of innovative therapies for Diabetes. My research interests include:
- receptors controlling beta cell function and survival
- intracellular signaling pathways controlling beta cell function and survival
- proteome and transcriptome
Éric
Renard
IGF Sud 001 04 67 33 83 82Know more >
Éric
Renard
PU-PH1, UM
Team: Stéphane Dalle - Éric Renard
EDUCATION
-
1996Ability for research direction - University of Montpellier - France
-
1995PhD in Biochemistry and Molecular Biology - University of Montpellier - France
-
1989Master in Nutrition and Food Science - University of Montpellier - France
-
1989Specialist in Nephrology - University of Montpellier - France
-
1988Specialist in Endocrinology and Metabolic Diseases, Faculty of Medicine - University of Montpellier - France
-
1987MD, Faculty of Medicine - University of Montpellier - France
POSITIONS HELD
-
1999-Professor of Endocrinology, Diabetes, Metabolic Diseases (Chair), Faculty of Medicine - University of Montpellier - France
-
1993-1999Assistant Professor of Endocrinology, Diabetes, Metabolic Diseases - University of Montpellier - France
-
1992-1993Arthur Sachs Research Fellow, Joslin Diabetes Centre, Harvard Medical School - Boston - MA - USA
-
1988-1992Lecturer of Endocrinology, Diabetes, Metabolic Diseases - Montpellier University Hospital - France
-
1983-1988Resident in Medicine - Montpellier University Hospital - France
HONORS / RESPONSABILITIES
-
2023-President of the French-speaking Diabetes Society
-
2020-Director of the Diabetes Cell Therapy Laboratory- Montpellier University Hospital - France
-
2012-Leader of Research Team on "Innovative therapeutics for diabetes: understanding and correction of insulin secretion dysfunction and loss" - Institute of Functional Genomics - Montpellier - France
-
2010-Head of Clinical Investigation Centre INSERM 1411- Montpellier University Hospital - France
-
2010-Head of Department of Endocrinology and Diabetes- Montpellier University Hospital - France
-
2008-2018Medical Director of Research and Innovation- Montpellier University Hospital - France
SKILLS / EXPERTISE
- My clinical research activity is dedicated to innovative intensive insulin therapy aiming at reproducing physiologic insulin delivery in people with diabetes. My research work is focused on wearable and implantable insulin pumps, continuous glucose monitoring, automated insulin delivery systems and pancreatic islet cell transplantation.
Researchers
Safia
Costes
IGF Sud 119 04 34 35 92 03Know more >
Safia
Costes
CRCN, Inserm
Team: Stéphane Dalle - Éric Renard
EDUCATION
-
2021Habilitation to conduct research - University of Montpellier - France
-
2007PhD in Biochemistry / Cellular and molecular biology - University of Montpellier - France
-
2003Master 2 - Cellular and molecular endocrinology - University of Montpellier - France
-
2002Master 1 - Cellular biology and physiology - University of Paris V - France
POSITIONS HELD
-
2015-Permanent researcher, CRCN INSERM - Institute of Functional Genomics - Montpellier - France
-
2008-2014Postdoctorate - Islet Research Center - University of California - Los Angeles - USA
-
2003-2007PhD/Thesis - Institut de Génomique Fonctionnelle - Montpellier - France
HONORS / RESPONSABILITIES
-
2023-2024Member of HCERES evaluation committee
-
2024RIPEC (C3) individual prime INSERM
-
2023"Gilberte et Jacques Tacussel" Prize, Académie Nationale de Médecine
-
2022-2027Member of the INSERM Specialized Scientific Committee CSS3 (elected)
-
2022-2025Coordinator of the ANSES research project
-
2017-Organizer of Montpellier Diabetes Day
-
2013"Young Investigator" prize from the Department of Medicine at UCLA, Los Angeles
-
2011AREDIC prize (Association for Research on Diabetes, Cerebral Failure and Cancer)
SKILLS / EXPERTISE
- I am a biologist specialized in understanding the physiology and pathophysiology of pancreatic beta cells. My research interests include:
- the identification of beta cell alteration mechanisms in type 2 diabetes
- the involvement of protein degradation pathways (ubiquitin/proteasome, autophagy)
- the proteotoxicity and alteration mechanisms common to type 2 diabetes and neurodegenerative diseases
Magalie
Ravier
IGF Sud 119 04 34 35 92 03Know more >
Magalie
Ravier
CRHC, Inserm
Team: Stéphane Dalle - Éric Renard
EDUCATION
-
2018Habilitation to conduct research - University of Montpellier - France
-
2001PhD in Biomedical Sciences (Endocrinology-Diabetes) - Catholic University of Louvain (UCL) - Brussels - Belgium
-
1997Master - Endocrinology - University of Montpellier - France
POSITIONS HELD
-
2009-Permanent researcher, CRCN INSERM - Institute of Functional Genomics - Montpellier - France
-
2006-2009Postdoctoral fellow - Catholic University of Louvain (UCL) - Brussels - Belgium
-
2002-2006Postdoctoral fellow - G.A. Rutter’s lab - Bristol University - Bristol - UK
-
1997-2002PhD student - JC Henquin’s lab - Catholic University of Louvain (UCL) - Brussels - Belgium
HONORS / RESPONSABILITIES
-
2024-Scientific Advisory Booard of French-speaking Foundation for Research into Diabetes (FFRD)
-
2023Member of HCERES evaluation committee
-
2021-Member of the Laboratory Council (elected) - Institute of Functional Genomics
-
2019-Associate Editor Frontiers in Endocrinology: Diabetes molecular mechanisms
-
2015-2021Co-leader of Research Team - Institute of Functional Genomics - Montpellier
-
2015-Manager of microscopy workstation Fura/FRET/opto - Institute of Functional Genomics
-
2017-Organizer of Montpellier Diabetes Day
-
2011Rising Star prize from European Association for the Study of Diabetes
-
2005Young researcher prize, Association for Research into Diabetes, Cerebral Insufficiency and Cancer (AREDIC)
SKILLS / EXPERTISE
- I am a physiologist/cell biologist specialized in the study of pancreatic islets of Langerhans. I study their physiological regulation and dysfunction in the context of type 2 diabetes. My scientific objectives are to identify the cellular and molecular mechanisms involved in the signaling pathways engaged by certain G protein-coupled receptors (GPCRs).
- I am particularly interested in GLP-1 and GIP receptors, which are therapeutic targets.
Orianne
Villard
IGF Sud 119 04 34 35 92 03Know more >
Orianne
Villard
PH, CHU
Team: Stéphane Dalle - Éric Renard
EDUCATION
-
2019PhD – Health & Biology – University of Montpellier
-
2016Medical Thesis – Endocrinology, Diabetology and Nutrition – Faculty of Medicine of Montpellier
-
2015Master 2 – Health & Biology – University of Montpellier
-
2008Master 1 – Functional Biology – University of Saint Etienne
POSITIONS HELD
-
2022-Chef de Clinique Assistant – Montpellier University Hospital - Montpellier
-
2020-2022Fellowship – University of Virginia – Charlottesville – USA
-
2019-2020Residency – University Hospital of Montpellier
-
2016-2019Thesis – Institute for Regenerative Medicine & Biotherapy – Montpellier
-
2014-2016Residency – Montpellier University Hospital – Montpellier
-
2014-2015Master 2 – Institute for Regenerative Medicine & Biotherapy – Montpellier
-
2012-2014Residency – Montpellier University Hospital – Montpellier
HONORS / RESPONSABILITIES
SKILLS / EXPERTISE
- I am a medical doctor specializing in Endocrinology and Diabetology with clinical expertise in the treatment and management of type 1 diabetes. My research interest is focus on new therapies for diabetes with two approaches: beta cell therapy and the development of new technological devices.
- I have experience in cell biology and ‘in vitro” laboratory techniques in particular with human beta cells (cultures of cell lines, molecular biology, work in BSL2 sector). I am the clinical coordinator of the islet transplant program in Montpellier and work with the human islet isolation platform in Montpellier.
- I am involved in a number of artificial pancreas clinical studies at the Montpellier University hospital, and I am interested in improving glycemic control and quality of life in patient with type 1 diabetes through the use of diabetes technology. I work closely with engineers and have experience on continuous glycemic data analysis.
Postdoctoral researchers and doctoral students
Ambrine
Arrar
IGF Sud 119 04 34 35 92 03Know more >
Ambrine
Arrar
Doctorant(e), Inserm
Team: Stéphane Dalle - Éric Renard
EDUCATION
POSITIONS HELD
HONORS / RESPONSABILITIES
SKILLS / EXPERTISE
Saad
El Mallem
IGF Sud 119 04 34 35 92 03Know more >
Saad
El Mallem
Doctorant(e), UM
Team: Stéphane Dalle - Éric Renard
EDUCATION
-
2023-2024UD in immuno-oncology at the University of Montpellier
-
2021-2023Master's degree in Biology-Health, specializing in Experimental and Regenerative Medicine at the University of Montpellier
-
2019-2021Bachelor's degree in Life Sciences, specializing in Animal Physiology and Neuroscience at the University of Montpellier
POSITIONS HELD
-
2024PhD student - Institute of Functional Genomics (IGF) - Montpellier - France
-
2023Master 2 internship (M.Ravier & S.Costes) - Institute of Functional Genomics (IGF) - Montpellier - France
-
2022Master 1 internship (C. Feillet-Coudray) - DMEM - Montpellier - France
HONORS / RESPONSABILITIES
SKILLS / EXPERTISE
- Reznik Y, Carvalho M, Fendri S, Prevost G, Chaillous L, Riveline JP, Hanaire H, Dubois S, Houéto P, Pasche H, Mianowska B, Renard E. Should people with type 2 diabetes treated by multiple daily insulin injections with home health care support be switched to hybrid closed-loop? The CLOSE AP+ randomized controlled trial. Diabetes Obes Metab. 2024 Feb;26(2):622-630. doi: 10.1111/dom.15351. PMID: 37921083
- Diallo A, Villard O, Carlos-Bolumbu M, Renard E, Galtier F. Effects of hypoglycaemic agents on reducing surrogate metabolic parameters for the prevention of cardiovascular events and death in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2024 Feb;26(2):495-502. doi: 10.1111/dom.15335. PMID: 37869934
- Renard E, Joubert M, Villard O, Dreves B, Reznik Y, Farret A, Place J, Breton MD, Kovatchev BP; iDCL Trial Research Group. Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial. Diabetes Care. 2023 Dec 1;46(12):2180-2187. doi: 10.2337/dc23-0685. PMID: 37729080
- Zaïmia N, Obeid J, Varrault A, Sabatier J, Broca C, Gilon P, Costes S, Bertrand G, Ravier MA. GLP-1 and GIP receptors signal through distinct b-arrestin 2-dependent pathways to regulate pancreatic b cell function. Cell Rep. 2023 Nov28;42(11):113326. doi: 10.1016/j.celrep.2023.113326. PMID: 37897727
- Coutant R, Bismuth E, Bonnemaison E, Dalla-Vale F, Morinais P, Perrard M, Trely J, Faure N, Bouhours-Nouet N, Levaillant L, Farret A, Storey C, Donzeau A, Poidvin A, Amsellem-Jager J, Place J, Quemener E, Hamel JF, Breton MD, Tubiana-Rufi N, Renard E. Hybrid Closed Loop Overcomes the Impact of Missed or Suboptimal Meal Boluses on Glucose Control in Children with Type 1 Diabetes Compared to Sensor-Augmented Pump Therapy. Diabetes Technol Ther. 2023 Jun;25(6):395-403. doi: 10.1089/dia.2022.0518. PMID: 36927054
- Dalle S, Abderrahmani A, Renard E. Pharmacological inhibitors of beta-cell dysfunction and death as therapeutics for Diabetes. Front Endocrinol. 2023 Mar 15;14:1076343. doi: 10.3389/fendo.2023.1076343. eCollection 2023. PMID: 37008937
- Brown MR, Laouteouet D, Delobel M, Villard O, Broca C, Bertrand G, Wojtusciszyn A, Dalle S, Ravier MA, Matveyenko AV, Costes S. The nuclear receptor REV-ERBα is implicated in the alteration of β-cell autophagy and survival under diabetogenic conditions. Cell Death Dis. 2022 Apr 15;13(4):353. doi: 10.1038/s41419-022-04767- PMID: 35428762
- Renard E, Tubiana-Rufi N, Bonnemaison E, Coutant R, Dalla-Vale F, Bismuth E, Faure N, Bouhours-Nouet N, Farret A, Storey C, Donzeau A, Poidvin A, Amsellem-Jager J, Place J, Breton MD; Free-life Kid AP Study Group. Outcomes of hybrid closed-loop insulin delivery activated 24/7 versus evening and night in free-living prepubertal children with type 1 diabetes: A multicentre, randomized clinical trial. Diabetes Obes Metab. 2022 Mar;24(3):511-521. doi: 10.1111/dom.14605. PMID: 34816597
- Costes S, Bertrand G, Ravier MA. Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies. Int J Mol Sci. 2021 May 18;22(10):5303. doi: 10.3390/ijms22105303. PMID: 34069914
- Ruiz L, Gurlo T, Ravier MA, Wojtusciszyn A, Mathieu J, Brown MR, Broca C, Bertrand G, Butler PC, Matveyenko AV, Dalle S, Costes S. Proteasomal degradation of the histone acetyl transferase p300 contributes to beta-cell injury in a diabetes environment. Cell Death Dis. 2018 May 22;9(6):600. doi: 10.1038/s41419-018-0603-0. PMID: 29789539
- Leduc M, Richard J, Costes S, Muller D, Varrault A, Compan V, Mathieu J, Tanti JF, Pagès G, Pouyssegur J, Bertrand G, Dalle S, Ravier MA. ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB. Diabetologia. 2017 Oct;60(10):1999-2010. doi: 10.1007/s00125-017-4356-6. PMID: 28721437
- Varin EM, Wojtusciszyn A, Broca C, Muller D, Ravier MA, Ceppo F, Renard E, Tanti JF, Dalle S. Inhibition of the MAP3 kinase Tpl2 protects rodent and human beta-cells from apoptosis and dysfunction by cytokines and enhances anti-inflammatory actions of exendin-4. Cell Death Dis. 2016 Jan 21;7(1):e2065. doi: 10.1038/cddis.2015.399. PMID: 26794660
Mechanisms of beta-cell alteration: involvement of amyloidogenic proteins and pesticides
Principal investigator
Safia COSTES
Inflammatory and metabolic stress of the pancreatic beta cell
Principal investigator
Stéphane DALLE
Automated insulin delivery by wearable or implantable systems
Principal investigator
Eric RENARD
Clinical development in diabetology: from cell therapy to new technologies
The clinical research projects of the Endocrinology-Diabetology Department at Montpellier University Hospital aim to develop:
- New technological modalities of insulin therapy for patients with diabetes in complex glycemic control situations such as gastroparesis, end-stage renal failure, or patients treated with multi-daily insulin injection. Our aim is to use continuous glucose measurement to optimize insulin therapy and make it accessible to all patients, including the most complicated.
- Cell therapy for diabetes, with an expertise on the isolation of human pancreatic islets (PRISM platform) and islet transplantation for patients with diabetes and high glycemic variability, hypoglycemia unawareness jeopardizing their quality of life and vital prognosis.
Current projects include:
• Evaluation of the efficacy of automated insulin delivery in patients with diabetes on hemodialysis: a randomized cross-over pilot study (AUTO-HEMODIAB)
• Real-life randomized controlled trial evaluating the effect of endoscopic pylorotomy by gastric POEM on glycemic control in patients with diabetes and gastroparesis (DIAPOEM)
• Evaluation of the performance and safety of the EkiYou Dose V2 application in patients with diabetes treated with multiple insulin injections
• Effect of islet transplantation on the incidence of diabetic complications and mortality in
type 1 diabetic patients (CPL-ILOT).
• Auto-islet transplantation in total pancreatoduodenectomy for benign disease of the duodenopancreas
IGF staff involved
Eric RENARD
PUPH, University of Montpellier
Orianne VILLARD
CC-AH University of Montpellier
Bader Al Taweel
CC Université de Montpellier
Anne FARRET
PH, Montpellier University Hospital
Publications
• Renard E., et al (2023) Diabetes Care, 46
• Villard O., et al. (2022) Diabetes Care, 45
• Lablanche S., et al (2021) Am J Transplant
Collaborations
• Antoine Debourdeau (Montpellier)
• Omar Diouri (Montpellier)
• Sandrine Lablanche (Grenoble)
• Marc Breton (Charlottesville)
Funding
• 2023-2025 : Société Francophone du Diabète (SFD 2023)
• 2023-2025 : Appel d’Offre Tremplin (CHU de Montpellier)
• 2023-2025 : Fonds Agir pour les Maladies Chroniques
• 2023-2024 : Adène Fonds de dotation
• 2023 : Prix de l’Innovation Numérique Diabète (Sanofi)
